VA
Viravaxx AG
viravaxx.com
Website unreachable since Oct 19, 2026
The startup develops a vaccine targeting hepatitis B by inducing a preS-specific immunoglobulin G IgG antibody response in both vaccine-naive adults and chronically infected patients. This approach aims to prevent hepatitis virus infection, addressing the significant public health challenge posed by the virus.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$4.4MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops a vaccine targeting hepatitis B by inducing a preS-specific immunoglobulin G IgG antibody response in both vaccine-naive adults and chronically infected patients. This approach aims to prevent hepatitis virus infection, addressing the significant public health challenge posed by the virus.